Eating on GLP-1 Medication
These drugs solve the intake problem and create a nutrition one: a fraction of the appetite, a stomach that empties slowly, and every mouthful having to earn its place. This section covers what to eat, what your appetite and digestion will actually do, how to keep muscle while the weight comes off, and how the individual medicines differ.
The guides
- What to Eat on GLP-1 Medication
Protein first, small and often, fibre and fluid on purpose: what to put on a plate you may not finish.
- Appetite and Digestion Changes to Expect on a GLP-1
Every change people report, when it typically arrives, why it happens, and the food-side response to each.
- Protein and Muscle on GLP-1 Medication
What the trials found about lean mass, and the two things that protect it: enough protein, and lifting.
- Foods That Make GLP-1 Side Effects Worse
What to pull back on, in order of how much difference it makes, and what to eat instead.
- GLP-1 Medications Compared: What Each One Means for Eating
Every drug people ask about, with its status stated plainly and its practical eating implications.
The medicines at a glance
Status is as at the review date below and changes frequently. The comparison guide gives each one a section: what the trials found, how appetite and digestion behave on it, and what it changes about how you eat.
| Medicine | What it acts on | How it is taken | Status |
|---|---|---|---|
| SemaglutideWegovy, Ozempic, Rybelsus | GLP-1 receptor agonist | Weekly injection, or a daily tablet | Licensed in the UK |
| TirzepatideMounjaro, Zepbound | Dual GIP and GLP-1 receptor agonist | Weekly injection | Licensed in the UK |
| LiraglutideSaxenda, Victoza | GLP-1 receptor agonist | Daily injection | Licensed in the UK |
| DulaglutideTrulicity | GLP-1 receptor agonist | Weekly injection | Licensed in the UK |
| ExenatideByetta, Bydureon | GLP-1 receptor agonist (the original one) | Twice-daily or weekly injection | Discontinued in the UK |
| OrforglipronFoundayo | Non-peptide GLP-1 receptor agonist (a small molecule, not an injectable peptide) | Daily tablet | Licensed elsewhere, not yet routine in the UK |
| Cagrilintide with semaglutide (CagriSema) | Amylin analogue combined with a GLP-1 receptor agonist | Weekly injection | Not approved anywhere |
| Retatrutide | Triple GIP, GLP-1 and glucagon receptor agonist | Weekly injection | Not approved anywhere |
Frequently asked questions
- What should I eat on a GLP-1 like Ozempic or Mounjaro?
- Protein first at every meal, small meals more often, less fat per sitting, and fibre and fluid on purpose rather than by accident. The drug handles the calorie restriction; your job is making sure the little you eat carries enough protein, fibre and fluid.
- What changes should I expect in my appetite and digestion?
- Appetite drops sharply, you feel full after a few bites, and gastrointestinal effects are common early on: nausea above all, plus constipation, diarrhoea, reflux and burping. They cluster around starting the drug and each dose increase, and mostly settle over the following weeks.
- How do I avoid losing muscle on a GLP-1?
- Eat roughly 1.2 to 1.6 g of protein per kg of body weight a day and lift weights two to three times a week. Body-composition substudies put lean tissue at roughly a quarter to two-fifths of the weight lost, which is what large fast weight loss does generally rather than something these drugs do uniquely.
- Does the advice change depending on which GLP-1 I take?
- The principles do not. What differs is the rhythm (a weekly injection concentrates side effects into the days after the dose), the size of the weight loss, and one practical exception: oral semaglutide must be taken on an empty stomach with nothing to eat or drink for at least 30 minutes afterwards.
- Is this medical advice?
- No. It is food guidance for people already prescribed these medicines. Nothing here covers doses, escalation or where to obtain anything, and symptoms like persistent vomiting or severe stomach pain are for your prescriber the same day, not for a diet change.
Elsewhere on the site
Written and reviewed by Mathew Beale, MSc Biotechnology, University of Reading.
Last reviewed: